Doors of deception-The diaspora of designer drugs

Drug Testing and Analysis

Volumn 3, Issue 9, 2011, Pages 527-531

  Kerwin, James ^a  

^a Jbe Ltd   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESIGNER DRUGS;

DESIGN;

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE; ATROPINE; BELLADONNA ALKALOID; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABIS; COCAINE; DESIGNER DRUG; G PROTEIN COUPLED RECEPTOR; GESTRINONE; HYOSCYAMINE; MESCALINE; NEUROTRANSMITTER; NICOTINE; OPIATE; PSILOCYBINE; SCOPOLAMINE; STEROID; TETRAHYDROCANNABINOL; TETRAHYDROGESTRINONE;

ALCOHOL INTOXICATION; CANNABIS ADDICTION; CHEMICAL ANALYSIS; CHEMICAL PROCEDURES; DATURA STRAMONIUM; DIVERSITY ORIENTED SYNTHESIS; DRUG DEPENDENCE; DRUG LEGISLATION; DRUG USE; FRAGMENT BASED SCREENING; GOVERNMENT; HUMAN; HYDROGENATION; LIPOPHILICITY; NOTE; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RESPIRATORY TRACT DISEASE; VIOLENCE;

EID: 80053395763     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.302     Document Type: Note

References (46)

1. W. Blake The Marriage of Heaven and Hell, 1794, Refer to republication of plates from facsimile of 1794 edition by Triana Press, Jura, France, 1960, subsequently reproduced by Dover Publications Incorporated, Mineola, New York, USA, 1994.
2. A. Huxley The Doors of Perception, Harper and Brothers: New York, USA, 1954.
3. R. J. Sullivan, E. H. Hagen Psychotropic substance-seeking: evolutionary pathology or adaptation? Addiction 2002, 97, 389.
4. EMCDDA. 2010 Annual Report on the State of the Drugs Problem in Europe, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, Portugal, 2010.
5. M. C. Logan, C. E. Hunter, R. J. Lokan, J. M. White, M. A. White The prevalence of alcohol, cannabinoids, benzodiazepines and stimulants amongst injured drivers and their role in driver culpability Part II: The relationship between drug prevalence and drug concentration, and driver culpability. Accid. Anal. Prev. 2000, 32, 623.
6. R. Mechoulam, L. Hanus A historical overview of chemical research on cannabinoids. Chem. Phys. Lipids 2000, 108, 1.
7. Y. Gaoni, R. Mechoulam Isolation, structure and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 1964, 86, 1646.
8. D. J. Harvey Metabolism of the cannabinoids. Rev. Biochem. Toxicol. 1984, 221.
9. W. L. Dewey Cannabinoid pharmacology. Pharmacol. Rev. 1986, 38, 151.
10. A. T. El-Alfy, K. Ivey, K. Robinson, S. Ahmed, M. Radman, D. Slade, I. Khan, M. Elsohly, S. Ross Antidepressant-like effect of delta-9-tetrahydrocannibinol and other cannabinoids isolated from Cannabis sativa L. Pharmacol. Biochem. Behav. 2010, 95, 434.
11. K. H. Lundstrom, M. L. Chiu (eds), G Protein-Coupled Receptors in Drug Discovery, CRC Press: Boca Raton, FL, USA, 2006, pp. 365.
12. L. A. Matsuda, S. J. Lolait, M. J. Brownstein, A. C. Young, T. I. Bonner Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346, 561.
13. S. Munro, K. L. Thomas, M. Abu-Shaar Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365, 61.
14. J.-P. Gong, E. S. Onaivi, H. Ishiguro, Q.-R. Liu, P. A. Agliaferro, A. Brusco, G. R. Uhl Cannabinoid CB2 receptors immunohistochemical localization in rat brain. Brain Res. 2006, 1071, 10.
15. O. Ofek, M. Karsak, N. LeClerc, M. Fogel, B. Frankel, K. Wright, J. Tam, M. Attar-Namdar, V. Kram, E. Shohami, R. Mechoulam, A. Zimmer, I. Bab Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc. Natl. Acad. Sci. USA 2006, 103, 696.
16. E. S. Graham, J. C. Ashton, M. Glass Cannabinoid receptors A brief history and what's hot. Frontiers Biosci. 2009, 14, 944.
17. L. S. Melvin, M. R. Johnson Structure-activity relationships of tricyclic and nonclassical bicyclic cannabinoids. NIDA Res. Monograph 1987, 79, 31.
18. D. H. Catlin, M. H. Sekera, B. D. Ahrens, B. Starcevic, Y. C. Chang, C. K. Hatton Tetrahydrogestrinone: Discovery, synthesis, and detection in urine. Rapid Commun. Mass Spectrom. 2004, 18, 1245.
19. F. A. Kekule Sur la constitution des substances aromatiques. Bulletin de la Societe Chimique de Paris 1865, 3, 98.
20. F. A. Kekulé Untersuchungen uber aromatische Verbindungen. Liebigs Annalen der Chemie 1866, 137, 129.
21. O. T. Benfey August Kekulé and the birth of the structural theory of organic chemistry in 1858. J. Chem. Edu. 1958, 35, 21.
22. J. Drews Drug discovery A historical perspective. Science 2000, 287, 1960.
23. L. P. Hammett Some relations between reaction rates and equilibrium constants. Chem. Rev. 1935, 17, 125.
24. C. Hansch, P. P. Maloney, T. Fujita, R. M. Muir Correlation of biological activity of phenoxyacetic acids with Hammett substituent constants and partition coefficients. Nature 1962, 194, 178.
25. C. Hansch, R. M. Muir, T. Fujita, P. P. Maloney, C. F. Geiger, M. Streich The correlation of biological activity of plant growth-regulators and chloromycetin derivatives with Hammett constants and partition coefficients, J. Am. Chem. Soc. 1963, 85, 2817.
26. T. Fujita, J. Iwasa, C. Hansch A new substituent constant, pi, derived from partition coefficients. J. Am. Chem. Soc. 1964, 86, 5175.
27. R. P. Verma, C. Hansch Understanding influenza neuraminidase inhibitors using quantitative structure-activity (QSAR) models, in Combating the Threat of Pandemic Influenza: Drug Discovery Approaches. (Ed: P.F. Torrance ). John Wiley & Sons: Hoboken, New Jersey, USA, 2007, pp. 209.
28. J. G. Topliss Utilization of operational schemes for analog synthesis in drug design. J. Med. Chem. 1972, 15, 1006.
29. J. G. Topliss Quantitative Structure-Activity Relationships of Drugs. Academic Press: New York, USA, 1983.
30. Recent Advances in QSAR Studies-Methods and Applications, (eds: T. Puzyn, J. Leszczynski, M. T. D. Cronin ). Springer-Verlag: New York, LLC USA, 2010, pp. 423.
31. J. Verma, V. M. Khedkar, E. C. Coutinho 3D-QSAR in drug design-A review. Curr. Topics Med. Chem. 2010, 10, 95.
32. P. J. Hadjuk Small molecules, great potential. Nature 2011, 470, 42.
33. P. Manoharan, R. S. K. Vijayan, N. Goshal Rationalizing fragment based drug discovery for BACE :1 Insights from FB-QSAR, multi-objective (MO-QSPR) and MIF studies. J. Computer Aided Mol. Discovery 2010, 24, 843.
34. W. R. J. D. Galloway, D. R. Spring Better leads come from diversity. Nature 2011, 470, 43.
35. F. Samms-Dodd Target-based drug discovery is something wrong ? Drug Discov. Today 2005, 10, 139.
36. X. Li, Y. Hu Identifying the cellular targets of bioactive small molecules with activity-based probes. Curr. Med. Chem. 2010, 17, 3030.
37. EMCDDA Thematic paper. Understanding the " Spice '' Phenomenon. European Monitoring Centre for Drugs & Drug Addiction: Lisbon, Portugal, 2009, pp. 37.
38. V. Auwarter, S. Dresen, W. Weinmann M. Muller, M. Putz, N. Ferreiros Spice and other herbal blends: harmless incense or cannabinoid designer drugs ? J. Mass Spectrom. 2009, 44, 832.
39. A. Shulgin Controlled Substances: Chemical and Legal Guide to Federal Drug Law. Ronin Publishers: Berkeley, CA, USA 1988, pp. 410.
40. A. Shulgin, A. Shulgin PiHKAL (Phenylethylamines I Have Known and Loved A Chemical Love Story). Transform Press: Berkeley, CA, USA 1991, pp. 1030.
41. A. Shulgin, A. Shulgin TiHKAL (Tryptamines I Have Known and Loved The Continuation). Transform Press: Berkeley, CA, USA 1997, pp. 832.
42. E. B. Russo, J. M. McPartland Cannabis is more than simply delta9-tetrahydrocannabinol. Psychopharmacol. 2003, 165, 431.
43. J. M. McPartland, E. B. Russo Cannabis and cannabis exracts Greater than the sum of their parts ? J. Cannabis Therapy 2001, 1, 103.
44. J. W. Fairbairn, J. T. Pickens Activity of Cannabis in relation to its delta 9-tetrahydrocannibinol content. Br. J. Pharmacol. 1981, 72, 401.
45. D. G. Barceloux Jimson weed and other belladonna alkaloids, in Medical toxicology of Natural Substances-Foods, Fungi, Medicinal Herbs, Plants and Venemous Animals. John Wiley and Sons: New Jersey, USA, 2008, pp. 776-783.
46. P. Teilhard de Chardin The Phenomenon of Man, Harper Torchbooks, The Cloister Library: Harper & Row, New York, NY USA, 1961, pp. 252.